

Theravance Biopharma, Inc.  
Form SC 13D/A  
May 13, 2016  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)\*

THERAVANCE BIOPHARMA, INC.

(Name of Issuer)

Ordinary Shares

(Title of Class of Securities)

G8807B106

(CUSIP Number)

Victoria A. Whyte  
GlaxoSmithKline plc  
980 Great West Road  
Brentford, Middlesex TW8 9GS  
England  
Telephone: +44 (0)208 047 5000

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

May 4, 2016

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

- NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
1. GlaxoSmithKline plc  
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(see instructions)
  2. (a)  
(b)
  3. SEC USE ONLY
  4. SOURCE OF FUNDS (see instructions)  
WC
  5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  
CITIZENSHIP OR PLACE OF ORGANIZATION
  6. England and Wales

- |   |                          |
|---|--------------------------|
|   | SOLE VOTING POWER        |
|   | 7. 9,644,807             |
|   | SHARED VOTING POWER      |
|   | 8. -0-                   |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | SOLE DISPOSITIVE POWER   |
|   | 9. 9,644,807             |
|   | SHARED DISPOSITIVE POWER |
|   | 10. -0-                  |

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
9,644,807
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
(see instructions)
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
20.3% (1)
14. TYPE OF REPORTING PERSON (see instructions)

CO

Footnotes:

- (1) Based on 47,421,691 Ordinary Shares outstanding as of May 4, 2016.

Cusip No. G8807B106 13 D/A1 Page 3 of 7

Item 1. Security and Issuer.

This Amendment No. 1 to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on March 24, 2015, with respect to the Ordinary Shares, par value \$0.00001 per share (the “Ordinary Shares”), of Theravance Biopharma, Inc., a Cayman Islands exempted company (the “Issuer”). GlaxoSmithKline plc is filing this amendment to reflect its new percentage beneficial ownership in the Issuer, which has decreased as a result of an increase in the outstanding Ordinary Shares of the Issuer. The Issuer’s principal executive offices are located at PO Box 309, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands.

Item 5. Interest in Securities of the Issuer.

(a) GlaxoSmithKline plc beneficially owns 9,644,807 Ordinary Shares, which represents 20.3% of 47,421,691 Ordinary Shares outstanding as of May 4, 2016.

Cusip No. G8807B106 13 D/A1 Page 4 of 7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: May 13, 2016

GLAXOSMITHKLINE PLC

By: /s/ Victoria A. Whyte

Victoria A. Whyte

Authorized Signatory

Cusip No. G8807B106 13 D/A1 Page 5 of 7  
SCHEDULE 1

Name	Business Address	Principal Occupation or Employment	Citizenship
Board of Directors	980 Great West Road		
Sir Andrew Witty	Brentford Middlesex, England TW8 9GS 980 Great West Road	Executive Director and Chief Executive Officer	British
Professor Sir Roy Anderson	Brentford Middlesex, England TW8 9GS 980 Great West Road	Company Director	British
Manvinder Singh Banga	Brentford Middlesex, England TW8 9GS 980 Great West Road	Company Director	Indian
Stacey Cartwright	Brentford Middlesex, England TW8 9GS 980 Great West Road	Company Director	British
Simon Dingemans	Brentford Middlesex, England TW8 9GS 980 Great West Road	Executive Director and Chief Financial Officer	British
Lynn Elsenhans	Brentford Middlesex, England TW8 9GS 980 Great West Road	Company Director	US
Dr. Jesse Goodman	Brentford Middlesex, England TW8 9GS 980 Great West Road	Company Director	US

Edgar Filing: Theravance Biopharma, Inc. - Form SC 13D/A

Middlesex, England

TW8 9GS  
980 Great West Road

Sir Philip Hampton	Brentford	Chairman and Company Director	British
	Middlesex, England		

TW8 9GS  
980 Great West Road

Judy Lewent	Brentford	Company Director	US
	Middlesex, England		

TW8 9GS



	980 Great West Road		
Urs Rohner	Brentford Middlesex, England	Company Director	Swiss
	TW8 9GS 2301 Renaissance Boulevard,		
Dr. Moncef Slaoui	King of Prussia PA, 19406	Executive Director and Chairman, Global Vaccines	Moroccan, Belgian & US
Corporate Executive Team			
	980 Great West Road		
Sir Andrew Witty	Brentford Middlesex, England	Executive Director and Chief Executive Officer	British
	TW8 9GS 980 Great West Road		
Roger Connor	Brentford Middlesex, England	President, Global Manufacturing & Supply	Irish
	TW8 9GS 980 Great West Road		
Simon Dingemans	Brentford Middlesex, England	Executive Director and Chief Financial Officer	British
	TW8 9GS 980 Great West Road		
Nick Hirons	Brentford Middlesex	Senior Vice President, Global Ethics and Compliance	British & US
	TW8 9GS		

Edgar Filing: Theravance Biopharma, Inc. - Form SC 13D/A

980 Great West Road

Brentford

Abbas Hussain

President, Global Pharmaceuticals

British

Middlesex, England

TW8 9GS

980 Great West Road

Brentford

David Redfern

Chief Strategy Officer

British

Middlesex, England

TW8 9GS

Cusip No. G8807B106 13 D/A1 Page 7 of 7

Dr. Moncef Slaoui	2301 Renaissance Boulevard, King of Prussia PA, 19406	Executive Director Chairman, Global Vaccines	Moroccan, Belgian & US
Claire Thomas	980 Great West Road Brentford Middlesex, England	Senior Vice President, Human Resources	British
Philip Thomson	TW8 9GS 980 Great West Road Brentford Middlesex, England	Senior Vice President, Communications and Government Affairs	British
Daniel Troy	TW8 9GS The Navy Yard 5 Crescent Drive Philadelphia, PA	Senior Vice President & General Counsel	US
Dr. Patrick Vallance	19112 980 Great West Road Brentford Middlesex, England	President, Pharmaceuticals R&D	British
Emma Walmsley	TW8 9GS 980 Great West Road Brentford Middlesex, England	Chief Executive Officer, GSK Consumer Healthcare	British
	TW8 9GS		